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OBJECTIVES: To evaluate the impact of Burkholderia cepacia complex colonization in cystic fibrosis patients
undergoing lung transplantation.
METHODS: We prospectively analyzed clinical data and respiratory tract samples (sputum and bronchoalveolar
lavage) collected from suppurative lung disease patients between January 2008 and November 2013. We also
subtyped different Burkholderia cepacia complex genotypes via DNA sequencing using primers against the recA
gene in samples collected between January 2012 and November 2013.
RESULTS: From 2008 to 2013, 34 lung transplants were performed on cystic fibrosis patients at our center.
Burkholderia cepacia complex was detected in 13 of the 34 (38.2%) patients. Seven of the 13 (53%) strains were
subjected to genotype analysis, from which three strains of B. metallica and four strains of B. cenocepacia were
identified. The mortality rate was 1/13 (7.6%), and this death was not related to B. cepacia infection.
CONCLUSION: The results of our study suggest that colonization by B. cepacia complex and even B. cenocepacia
in patients with cystic fibrosis should not be considered an absolute contraindication to lung transplantation in
Brazilian centers.
KEYWORDS: Lung Transplantation; Cystic Fibrosis; Burkholderia Cepacia Complex; Burkholderia cenocepacia;
Prognosis.
’ INTRODUCTION
Lung transplantation (LTx) can prolong the survival of and
improve the quality of life for patients with reduced lung
function and short life expectancy, and the procedure is used
as the final therapeutic option for end-stage lung disease in
more than 150 centers worldwide (1).
The number of patients on waiting lists for LTx has increased
in recent years, surpassing the number of organs available
for the procedure. Consequently, the waiting-list mortality
rate has increased to up to 50% in some countries (2).
In Brazil, in the first three months of 2015, the rate of donor-
lung utilization was only 4.1%, which is much lower than
the expected average of 15%. This deficiency has con-
tributed to a waiting-list mortality rate of 10% (3).
Contraindications to transplantation such as comorbid-
ities, poor prognosis and post-transplant complications must
be considered when selecting candidates for inclusion on
waiting lists (2,4).
Cystic fibrosis (CF) patients are often colonized by multi-
ple bacterial species. Despite its low prevalence, Burkholderia
cepacia complex (BCC) colonization has been associated with
a poorer prognosis after LTx. This bacterial complex includes
20 genotypically distinct species or ‘‘genomovars’’ (5-9), and
the most severe infections seem to be related to genomovar
III (B. cenocepacia) (10,11).
Recent studies have confirmed an association between the
presence of genomovar III and reduced survival after LTx (12-14).
Because of this relationship, some centers have begun to exclude
patients colonized by B. cenocepacia from waiting lists for LTx.DOI: 10.6061/clinics/2018/e166
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In our center, over 50% of bilateral transplants are per-
formed in patients with suppurative disease, 26% of whom
are CF patients. The transplants have resulted in very good
outcomes, with an overall survival of 55.2% after 5 years (15).
Furthermore, unlike other groups, we have not observed
an increased morbidity in CF patients colonized by BCC.
Therefore, the aim of the current study is to describe the
incidence of preoperative colonization by BCC in candidates
for LTx at our lung transplant center and to analyze the
impact of this colonization on clinical outcomes after LTx.
’ METHODS
The current study used a prospective cohort design.
Clinical data and microbiology results were collected for all
patients (adults and children) with CF who underwent LTx
between January 2008 and November 2013 at the Heart
Institute of Sao Paulo Medical School (InCor – HCFMUSP).
The two ethics committees at this institute approved the
research.
Clinical data were prospectively collected to compare
clinical outcomes after LTx between CF patients colonized or
not colonized by Burkholderia cepacia complex.
The surgical and clinical protocols are described below.
Surgery technique: All included patients underwent bilateral
LTx via a bilateral thoracotomy (clamshell incision) with
insertion of two pleural drainage tubes on each side of the
thorax.
Immunosuppression protocol: For induction of immunosup-
pressive treatment, all patients received methylprednisolone
(500 mg during surgery) and basiliximab (20 mg during
surgery and on day 4). For maintenance immunosuppres-
sion therapy, tacrolimus (0.15 mg/kg/d), azathioprine
(2 mg/kg/d) and prednisone (0.5 mg/kg/d) were used for
1 month with dose reductions over the following months.
After November 2010, our initial immunosuppressive protocol
was changed to cyclosporine (5 mg/kg bid), mycophenolate
sodium (10 mg/kg bid up to 1440 mg/d) and prednisone
(0.5 mg/kg/d) for all CF patients due to the lower diabe-
togenic profile than tacrolimus-based schemes.
Monitoring and treatment of acute rejection episodes: Surveil-
lance fiber optic bronchoscopy was performed in the second
and sixth weeks after transplantation and then in months 3,
6, 9 and 12 or when clinically indicated. Acute rejection
episodes were always treated with a 3-day pulse of methyl-
prednisolone (10 mg/kg/d up to 1 g/d) when biopsies were
graded as A2 or higher according to the International Society
of Heart and Lung Transplant revision of the 1996 working
formulation for the standardization of nomenclature in the
diagnosis of lung rejection (16). Perivascular infiltrates graded
as A1 and bronchiolar lymphocytic infiltrates had individua-
lized therapeutic strategies.
Bacterial prophylaxis: Antibiotics were chosen based on
pre-transplant culture sputum results. All patients colonized
with BCC were treated with at least two drugs (trimethoprim-
sulfamethoxazole and meropenem) until intraoperative cul-
tures of bronchial aspiration and bronchoalveolar lavage
samples were available. Inhaled antibiotics (tobramycin or
colistin) were also used for all CF patients. Sputum culture
samples were collected from all patients on the waiting list
every 3 to 6 months and in cases of acute exacerbation.
Microbiology: Respiratory tract samples were plated on selec-
tive agar for B. cepacia and incubated at 37oC for 72 hours
(Oxoid, USA). Isolated strains were identified using a Vitek
automated system (bioMérieuxVitek Inc., Marcy-L’Etoile,
France); specifically, the strains were subjected to sensitivity
testing against meropenem, ceftazidime, and trimethoprim-
sulfamethoxazole. This technique was performed in accor-
dance with the guidelines recommended by the Clinical and
Laboratory Standards Institute (CLSI 2010) (17).
Molecular biology: Genotyping was performed using capil-
lary electrophoresis sequencing. Molecular analysis of
B. cepacia genotypes was performed using DNA sequencing
primers against the recA11 (18) gene. After the amplifica-
tion of DNA fragments, automatic sequencing, alignment
and phylogenetic analysis were performed on the sequences.
Evolutionary relationships between recA genes were deter-
mined through data analysis using the software Molecular
Biology. DNA extraction was performed on positive samples
using a QIAamps DNA minikit (Qiagen, Germany). The
partial recA gene of the Burkholderia genome was amplified
as reported by Payne et al (2005). Sequencing reactions were
performed using a Bigdye Terminator v.3.1 Cycle Sequencing
Ready Reaction Kit on an ABI PRISMDye Deoxy Terminator
Automatic DNA sequencer (Applied Biosystems Inc., Foster
City, CA, USA).
Phylogenetic analysis: Sequences were aligned using Sequen-
cer version 4.1.4. A maximum likelihood (ML) phylogenetic
tree was generated. The same model was also used to estimate
maximum a posteriori (MAP) trees using a Bayesian Markov
Chain Monte Carlo (MCMC) method.
Statistical analysis: All analyses were performed using
SPSS software, version 13.0. For univariate analysis and
to estimate the independent effects of variables, a Cox pro-
portional hazards model was used with 95% confidence
intervals. P o 0.05 was considered statistically significant.
The Kaplan-Meier method was used to generate survival
curves. Nine independent categorical variables were ana-
lyzed via univariate Cox regression analysis: age, sex,
body mass index (BMI), colonization by BCC, primary graft
dysfunction (PGD), acute rejection episodes, chronic rejec-
tion, days in intensive care unit (ICU) and days until
hospital discharge after transplantation.
’ RESULTS
Between 2008 and 2013, 130 lung transplants were perfor-
med at our institution. Overall, 62 (47.6%) transplantations
were performed in patients with suppurative lung disease,
and 34 (26.1% of the total) of these patients had CF.
BCC was identified in 13 patients with CF. Among these,
seven strains of BCC were genetically analyzed: 3 were identi-
fied as strains of Burkholderia metallica and 4 as strains of
Burkholderia cenocepacia. Regarding the prevalence of colo-
nization with other bacteria, 55% (19/34) of the CF patients
were positive for Staphylococcus aureus and 82% (28/34) for
Pseudomonas aeruginosa.
Burkholderia cepacia complex infection and clinical
outcomes
During follow-up, the mortality rate was 17.6% (6/34).
Among the six CF patients who died after LTx, only one was
previously colonized by BCC. However, this patient’s death
was attributed to hospital-acquired pneumonia and septic
shock due to multi-drug-resistant Acinetobacter baumannii.
Of note, no BCC-positive cultures were identified among the
samples collected during post-transplant follow-up.
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The characteristics and clinical outcomes of the CF patients
included in our study are summarized in Table 1. The results
from the univariate analysis are shown in Table 2. BCC-
colonized and non-BCC-colonized patients showed no dif-
ferences in mortality rate, length of ICU stay, length of hospital
stay, primary graft dysfunction, acute rejection or allograft
chronic dysfunction (Table 2 and Figure 1). Of special interest,
whether a patient was colonized with the BCC strains
B. metallica or B. cenocepacia did not impact the mortality
rate after LTx (Figure 2).
’ DISCUSSION
LTx recipients should be rationally selected based on
considerations of the risk of mortality without a transplant,
the chance of patient survival after transplantation and the
expected time on the waiting list (2,3). Identifying and exclud-
ing possible causes of increased post-transplant mortality
can optimize LTx survival outcomes and even reduce the
waiting list length. Indeed, some centers have found that
both short- and long-term survival are significantly lower
for patients preoperatively infected with B. cenocepacia,
leading to the difficult decision to stop listing these
patients (12-14).
CF is the third most common indication for lung trans-
plantation. Interestingly, despite that CF involves multiple
organs and has characteristics that could aggravate mor-
bidity and mortality after LTx, CF patients have shown the
best survival rates after transplantation compared to all other
indications (19).
In contrast with previous investigations of CF patients and
BCC colonization, our study found no difference in post-LTx
survival between patients colonized and not colonized with
BCC, even in a separate analysis of B. cenocepacia colonization.
Indeed, only one death occurred among the B. cenocepacia-
colonized patients, and the cause of death was attributed to
hospital-acquired Acinetobacter baumannii infection. Thus,
this case did not indicate that BCC increased the risk of
septic complications. No evidence of BCC colonization
was identified in any culture sample after the transplant
procedure.
Literature regarding the impact of BCC colonization on
transplant outcomes is controversial. Older studies have
shown poor post-transplant survival of patients colonized
by BCC, with survival rates of 50% and 83% being reported
for BCC-infected and non-infected patients, respectively
(p = 0.006). However, virulence markers and specific BCC
subtypes (e.g., B. cenocepacia - genomovar III) have been
directly related to worse prognosis after transplantation (11).
More recently, The Freeman Hospital (UK) LTx group exam-
ined a cohort of 22 BCC-infected CF patients, including
patients infected with B. cenocepacia and other BCC genomo-
vars, and found no significant decrease in survival (14);
however, the specific mortality of patients infected with
genomovar III (B. cenocepacia) was excessively high (75%).
Lung transplant centers in North America and France have
also published data on this topic, with similar conclusions
to our study, namely, that colonization by BCC does not
impact post-LTx survival and is therefore not a reason
to exclude colonized CF patients from LTx waiting lists.
However, careful screening of BCC-infected patients is
recommended, and healthcare providers should be aware
that post-transplant mortality among BCC-infected patients
with CF varies by infecting species. For example, B. cenocepacia
Table 1 - Characteristics of the study population and distributions of clinical outcomes among subgroups.
Not infected
(n = 21)
B. cenocepacia
(n = 4)
B. metallica
(n = 3)
BCC No genomovar
available (n = 6)
Age (yr) 22.52 ± 7.06 27 ± 11.34 26.33 ± 14.57 29.33 ± 10.38
Gender 8 F/13 M 3 F/1 M 2 F/1 M 3 F/3 M
BMI 18.66 ± 3.76 19.52 ± 5.10 19.5 ± 2.16 19.77 ± 3.95
Days of ICU stay after transplantation 11.05 ± 11.37 22.75 ± 21.76 13 ± 13.86 10.5 ± 4.50
Days of hospital stay after transplantation 55.29 ± 23.87 52.5 ± 24.12 59.67 ± 34.79 43.16 ± 16.51
Time since transplantation (mo) 36.43 ± 23.87 17.75 ± 10.90 48 ± 31.43 41.5 ± 9.09
Death (yes/no) 5 1 none none
PGD 4 2 1 none
Chronic rejection (yes/no) 2 1 2 2
Acute rejection (yes/no) 11 3 1 5
Antibiotic sensitivity - 1 yes/3 no 2 yes/1 no 3 yes/3 no
BMI: body mass index; ICU: intensive care unit; PGD: primary graft dysfunction.
Table 2 - Univariate cox regression analysis.
Variable HR CI (95%) p
Length of hospital stay after transplantation 1.017 0.970 - 1.066 0.487
Length of ICU stay after transplantation 1.045 0.993 - 1.099 0.090
BCC infection (yes/no) 0.312 0.036 - 2.674 0.288
PGD (yes/no) 0.732 0.086 - 6.271 0.776
Gender 0.459 0.083 - 2.554 0.374
BMI (p18.5/418.5) 2.141 0.392 - 11.726 0.379
Age (yr) 0.990 0.904 - 1.085 0.832
Chronic rejection (yes/no) 0.631 0.073 - 5.449 0.675
Acute rejection (yes/no) 0.581 0.116 - 2.898 0.507
ICU: intensive care unit; BCC: Burkholderia cepacia complex; PGD: primary graft dysfunction; BMI: body mass index.
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Figure 1 - Kaplan-Meier survival curves for cystic fibrosis patients who underwent lung transplantation classified by Burkholderia
cepacia complex infection status.
Figure 2 - Kaplan-Meier Survival curves for patients with cystic fibrosis who underwent lung transplantation classified by B. cenocepacia
infection status.
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was not associated with an unacceptably high risk of a fatal
outcome after LTx, although a relationship with poorer
long-term survival was found (20,21).
Regarding our cohort, the small number of patients, espe-
cially those colonized with B. cenocepacia (only 4 patients),
is certainly a limitation of the study. However, this is the only
study conducted to date examining a Brazilian population
that has matched BCC genomovar findings with good
clinical outcomes.
There was a difference in mortality related to B. cenocepacia
infection in our study compared to previous reports, and this
discrepancy may be related to host factors. The relationship
between the genetic determinants in the population, the host
immune response and the interaction between B. cenocepacia
and the respiratory microbiome of CF patients from Brazil
has never been studied. It should be noted that all B. cenocepacia
strains may not exhibit the same behavior and that the
strain identified in our cohort was potentially less virulent
than those present in other centers.
Although our sample size was small, we did not find that
CF patients colonized by BCC exhibited a worse prognosis
after LTx, even patients infected with B. metallica or B. cenocepacia.
Based on these results, we suggest that BCC colonization
(even with genomovar III) should not be a contraindication
for LTx in CF patients in Brazil. The potential that both CF
patients and B. cenocepacia strains exhibit different char-
acteristics depending on world location is intriguing, and a
clearer understanding of these differences should be sought
moving forward.
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